Dannis Chang

Dannis Chang, PharmD. is currently the Senior Director and Head of Global Medical Information and Scientific Communications at Halozyme Therapeutics, leading the development and establishment of the vision, overarching goals and objectives, and key strategic focus areas and tactics for Medical Information, Medical Communications, and Operations within Global Medical and Scientific Affairs. He received his undergraduate degree in Molecular and Cellular Biology from University of California – Berkeley, and upon graduation, he’s worked in project management at Genentech in the Translational and Molecular Oncology Division, as well as in research discovery and sales and marketing at LifeScan and AnaSpec Inc, respectively. Dannis also received a Doctor of Pharmacy (PharmD) degree from the University of Southern California and completed a post‐doctoral Fellowship with Novartis Oncology in US and Global Clinical Development and Scientific Affairs Division where he’s supported and led various efforts that involved US and Global Medical Information services, MSL Strategy and Operations, Managed Markets and Payer Access, and publications. During his fellowship, he also served as an adjunct faculty at the Ernest Mario School of Pharmacy at Rutgers University. Post fellowship training, Dannis joined Genentech as the Senior Product Lead in Medical Communications supporting Avastin in the lung, renal cell, and gynecologic cancer indications, and was accountable for the development and execution of various medical information duties. He also served as the Medical Science Director for Tecentriq in the genitourinary cancer medical team, where he’s made numerous contributions in preparation for the initial launch in 2L metastatic bladder cancer, and other launch readiness and post-market activities from a commercial and medical affairs capacity. Dannis was also the strategic program lead within Medical Business Operations, where he focused on developing system-wide capabilities to improve healthcare outcomes and enable the organization to apply the latest scientific and technological advances to resolve significant issues within the business, thus reducing operating costs and redundancies, and increase efficiencies across teams. Dannis joined Chinese Bioscience Association in 2018 as a volunteer and supported various activities such as the Cancer Immunotherapy Symposium, Member Picnic, and Annual Conference.